Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
MitraClip EXPAND G4 Study
NCT04177394 · View on ClinicalTrials.gov ↗
Study Summary
This primary objective of the EXPAND G4 study is to confirm the safety and performance of the MitraClip G4 System in a post-market setting.
Conditions Studied
Interventions
- DEVICE MitraClip G4 System
Study Locations (20)
New York
- Albany Medical Center — Albany
- NYU Langone Health — New York
- Mount Sinai Hospital — New York
- Hudson Valley Cardiovascular Practice, P.C. — Poughkeepsie
California
- Scripps Health — La Jolla
- University of California - Davis Medical Center — Sacramento
- Los Robles Regional Medical Center — Thousand Oaks
Alabama
- University of Alabama at Birmingham — Birmingham
- Cardiology Associates of Mobile, Inc. — Mobile
Illinois
- Northshore University Health System — Evanston
- Prairie Education & Research — Springfield
Arkansas
- Arkansas Heart Hospital — Little Rock
Connecticut
- Cardiology Associates of Fairfield County, PC — Norwalk
Florida
- NCH Healthcare System — Naples
Kansas
- Via Christi — Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,164 participants |
| Start Date | 2020-01-17 |
| Est. Completion | 2028-03 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04177394
The ClinicalTrials.gov registry entry for NCT04177394 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Mitral Regurgitation appearing as the primary indexed condition, and to 1 intervention — of which MitraClip G4 System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04177394 reports 20 study locations spanning 13 distinct geographic areas — top geographies include New York, California, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04177394 about?
NCT04177394 is a clinical study titled "MitraClip EXPAND G4 Study". This primary objective of the EXPAND G4 study is to confirm the safety and performance of the MitraClip G4 System in a post-market setting.
What is the current status of trial NCT04177394?
This trial is currently active not recruiting. The enrollment target is 1,164 participants. The study started on 2020-01-17. Estimated completion is 2028-03.
What conditions does trial NCT04177394 study?
This clinical trial studies the following conditions: Mitral Regurgitation, Mitral Valve Regurgitation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04177394?
The interventions under investigation include: MitraClip G4 System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04177394?
This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04177394 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.